Athira Pharma Form 144 shows July 2025 insider share sale

Rhea-AI Filing Summary

Athira Pharma, Inc. (ticker ATHA) has filed a Form 144, notifying the SEC of an intended insider sale of up to 8,526 common shares through broker Morgan Stanley Smith Barney LLC. The proposed sale is scheduled for 01 July 2025 on Nasdaq. The shares were recently acquired on 30 June 2025 via a restricted-stock lapse tied to equity compensation. With 39,042,445 total shares outstanding, the transaction represents roughly 0.02 % of the float, indicating minimal dilution or market impact. No prior sales were reported in the past three months, and the filer affirms no undisclosed adverse information. Overall, this appears to be a routine liquidity move rather than a signal of fundamental change.

Positive

• None.

Negative

• Insider intends to sell 8,526 shares, which, although immaterial in size, can be perceived as a slight negative sentiment signal.

Insights

Financial Analyst

TL;DR Minor insider Form 144: 8,526 shares (0.02 %) slated for 1-Jul-25 sale; routine, low market impact.

The filing signals an insider’s intent to monetize a portion of recently vested restricted stock. At just 8,526 shares against 39 million outstanding, the sale’s dollar value ($2,502 as stated) and volume are negligible, unlikely to affect liquidity or price discovery. Rule 144 requires advance notice, and the filer certifies no non-public negative information. While any insider sale can raise questions about sentiment, the size, timing (immediately after vesting), and use of a reputable broker suggest a standard diversification transaction rather than lack of confidence. I classify the event as neutral for investors.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Fl. New York NY 10004	8526	2502	39042445	07/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/30/2025	Restricted Stock Lapse - See Remarks	Athira Pharma, Inc.			36666	07/01/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Athira Pharma (ATHA) file with the SEC?

ATHA submitted a Form 144, a notice of proposed insider sale under Rule 144.

How many ATHA shares are planned for sale?

The filing covers 8,526 common shares.

When is the expected sale date for the ATHA shares?

The approximate sale date disclosed is 01 July 2025.

What percentage of Athira Pharma’s outstanding shares does the sale represent?

Roughly 0.02 % of the 39,042,445 shares outstanding.

Which broker is handling the transaction?

Morgan Stanley Smith Barney LLC’s Executive Financial Services division.